<DOC>
	<DOCNO>NCT01787552</DOCNO>
	<brief_summary>The purpose phase Ib/II clinical trial : ) evaluate safety co-administration LDE225 INC424 myelofibrosis patient establish maximum tolerated dose and/or Recommended Phase II dose combination b ) ass efficacy co-administration LDE225 INC424 spleen volume reduction .</brief_summary>
	<brief_title>A Phase Ib/II Dose-finding Study Assess Safety Efficacy LDE225 + INC424 Patients With MF</brief_title>
	<detailed_description>The purpose phase Ib/II clinical trial : ) evaluate safety co-administration LDE225 INC424 myelofibrosis patient establish maximum tolerated dose and/or Recommended Phase II dose combination b ) ass efficacy co-administration LDE225 INC424 spleen volume reduction . Adult patient , age ≥ 18 year , myelofibrosis meet intermediate high risk prognostic criterion exhibit palpable splenomegaly ≥ 5 cm leave costal margin previously treat JAK Smo inhibitor eligible study . Approximately 36 patient participate Phase Ib dose escalation safety expansion part study . Dose escalation dependent available toxicity information ( include adverse event DLTs ) , PK , PD , efficacy information , well recommendation Bayesian Logistic Regression Model ( BLRM ) . In Phase II part study approximately 46 patient enrol : 18 patient enrol Stage 1 , follow interim analysis minimum number responder observe , 28 additional patient enrol stage 2 . If less minimum number responder observe Stage 1 enrollment halt . Approximately 82 patient enrol entire study .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Hematologic Diseases</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<mesh_term>Bone Marrow Diseases</mesh_term>
	<mesh_term>Blood Platelet Disorders</mesh_term>
	<mesh_term>Hemorrhagic Disorders</mesh_term>
	<mesh_term>Thrombocythemia , Essential</mesh_term>
	<criteria>Diagnosed PMF per 2008 WHO criterion , postPV MF postET MF per IWGMRT criterion . Ineligible unwilling undergo stem cell transplantion . PLT count &gt; = 75X 10^9/L reach aid transfusion . ECOG performance status ≤ 2 . Palpable splenomegaly define ≥ 5 cm leave costal margin . Intermediate risk level 1 ( 1 prognostic factor age ) , Intermediate risk level 2 , high risk . Active symptom MF demonstrate one symptom score least 5 ( 0 to10 point scale ) two symptom score least 3 ( 0 10 point scale ) MF Symptom Assessment Form ( MFSAF ) . Previous therapy JAK Smoothened inhibitor . Patient currently medication interfere coagulation ( include warfarin ) platelet function exception low dose aspirin ( 100 mg ) LMWH . Impairment GI function GI disease may significantly alter absorption INC424 LDE225 ( e.g. , uncontrolled nausea , vomit , diarrhea ; malabsorption syndrome ; small bowel resection ) . Splenic irradiation within 12 month prior Screening . Pregnant nursing woman . WOCBP use highly effective method contraception Sexually active male refuse condom use Patients neuromuscular disorder ( e.g . inflammatory myopathy , muscular dystrophy , amyotrophic lateral sclerosis spinal muscular atrophy ) concomitant treatment drug recognize cause rhabdomyolysis , HMG CoA inhibitor ( statin ) , clofibrate gemfibrozil . Pravastatin may use necessary , extra caution .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Dose escalation</keyword>
	<keyword>Maximum Tolerated Dose</keyword>
	<keyword>MTD</keyword>
	<keyword>Safety Expansion</keyword>
	<keyword>Safety</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Myelofibrosis</keyword>
	<keyword>Post-polycythemia vera myelofbrosis ( Post PV-PMF )</keyword>
	<keyword>Post essential thrombocythemia myelofibrosis ( Post ET-MF )</keyword>
	<keyword>Primary myelofibrosis ( PMF )</keyword>
	<keyword>Intermediate risk myelofibrosis</keyword>
	<keyword>High risk myelofibrosis</keyword>
	<keyword>Combination Treatment</keyword>
	<keyword>Hedgehog Signaling Pathway</keyword>
	<keyword>Smoothened inhibitor</keyword>
	<keyword>JAK inhibitor</keyword>
</DOC>